A key factor driving the growth of the global sinusitis drugs market is the rise in the prevalence of sinusitis. This has called out for a rising need for identifying and manufacturing sinusitis drugs among the several stakeholders of the healthcare industry.
North America led the market in 2018, followed by Europe, Asia, and ROW respectively. The market growth in North America can be attributed to the increased investments in R&D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region.
Global sinusitis drugs market: Advent of biologics
The emergence of biologics is one of the critical trends gaining traction in the sinusitis drugs market. People with chronic rhinosinusitis are being treated with the therapeutic use of biologics. Approvals for Omalizumab, a recombinant humanized monoclonal antibody has been done for the treatment of severe allergic asthma in the US and Europe. Furthermore, Omalizumab is being evaluated by scientists on the parameters of safety and efficacy in treating chronic rhinosinusitis with nasal polyps. Thus, the rapidly advancing emergence of biologics is likely to drive the sinusitis drugs market growth in the forthcoming years.